Literature DB >> 21420200

[Cardiovascular risk in Spanish smokers compared to non-smokers: RETRATOS study].

Jaime Fernández de Bobadilla1, Verónica Sanz de Burgoa, Patricio Garrido Morales, Esteban López de Sá.   

Abstract

AIM: To evaluate the level of cardiovascular risk in smokers seenin Primary Care clinics.
DESIGN: Epidemiologic, cross-sectional and multicentre study.
SETTING: Primary Care. PATIENTS: Every investigator included 4 consecutive patients (3 smokers, 1 non-smoker) aged 35-50 years, who came to the clinic for any reason. A total of 2,184 patients were included; 2,124 (1,597 smokers; 527 non-smokers) were evaluated and 60 patients were excluded because they did not meet with selection criteria. MEASUREMENTS: The 10-year risk of suffering from a fatal cardiovascular disease (CVDR) was calculated according to the SCORE (Systematic Coronary Risk Evaluation) model. The 10-year lethal CVR according SCORE model, was classified as: very high (> 15%), high (10-14%), slightly high (5-9%), average (3-4%), low (2%), very low (1%) and negligible (< 1%). A logistical regression model was used to estimate the relationship between smoking and prior cardiovascular events.
RESULTS: 10-year fatal CVDR according to the SCORE model was significantly higher in smokers (40±5.3) vs. non-smokers (1.9±2.5) (P<.0001). RISK STRATIFICATION: low (< 3%) [78.0% non-smokers vs. 60.7% smokers (P<.0001)]; intermediate (3-5%) [11.1% non-smokers vs. 12.6% smokers (P<.001)]; high (> 5%) [10.9% non-smokers vs. 26.7% smokers (P<.001)]. The logistical regression model showed that non-smokers vs. smokers had less probability of suffering myocardial infarction (OR 0.3; 95% confidence interval (95% CI): 0.1-0.8; P<.0001), peripheral vascular disease (OR 0.6; 95% CI: 0.4-1.0; P=.0180) and chronic obstructive lung disease (OR 0.18; 95% CI: 0.1-0.2; P=.0507).
CONCLUSIONS: Smoking is related to a high risk of fatal cardiovascular disease. Active promotion in Primary Care clinics of measures aimed at reducing the prevalence of the smoking habit would lead to a lowering of cardiovascular morbidity and mortality. Copyright Â
© 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21420200      PMCID: PMC7025142          DOI: 10.1016/j.aprim.2010.10.005

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  31 in total

1.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Guy De Backer; Anna Dominiczak; Renata Cifkova; Robert Fagard; Giuseppe Germano; Guido Grassi; Anthony M Heagerty; Sverre E Kjeldsen; Stephane Laurent; Krzysztof Narkiewicz; Luis Ruilope; Andrzej Rynkiewicz; Roland E Schmieder; Harry A J Struijker Boudier; Alberto Zanchetti; Alec Vahanian; John Camm; Raffaele De Caterina; Veronica Dean; Kenneth Dickstein; Gerasimos Filippatos; Christian Funck-Brentano; Irene Hellemans; Steen Dalby Kristensen; Keith McGregor; Udo Sechtem; Sigmund Silber; Michal Tendera; Petr Widimsky; José Luis Zamorano; Serap Erdine; Wolfgang Kiowski; Enrico Agabiti-Rosei; Ettore Ambrosioni; Lars H Lindholm; Margus Viigimaa; Stamatis Adamopoulos; Enrico Agabiti-Rosei; Ettore Ambrosioni; Vicente Bertomeu; Denis Clement; Serap Erdine; Csaba Farsang; Dan Gaita; Gregory Lip; Jean-Michel Mallion; Athanasios J Manolis; Peter M Nilsson; Eoin O'Brien; Piotr Ponikowski; Josep Redon; Frank Ruschitzka; Juan Tamargo; Pieter van Zwieten; Bernard Waeber; Bryan Williams
Journal:  J Hypertens       Date:  2007-06       Impact factor: 4.844

2.  Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.

Authors: 
Journal:  Eur Heart J       Date:  1998-10       Impact factor: 29.983

3.  Registration and management of smoking behaviour in patients with coronary heart disease. The EUROASPIRE survey.

Authors:  T F van Berkel; H Boersma; D De Baquer; J W Deckers; D Wood
Journal:  Eur Heart J       Date:  1999-11       Impact factor: 29.983

4.  Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease: Edinburgh Artery Study.

Authors:  J F Price; P I Mowbray; A J Lee; A Rumley; G D Lowe; F G Fowkes
Journal:  Eur Heart J       Date:  1999-03       Impact factor: 29.983

5.  Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study.

Authors:  Koon K Teo; Stephanie Ounpuu; Steven Hawken; M R Pandey; Vicent Valentin; David Hunt; Rafael Diaz; Wafa Rashed; Rosario Freeman; Lixin Jiang; Xiaofei Zhang; Salim Yusuf
Journal:  Lancet       Date:  2006-08-19       Impact factor: 79.321

Review 6.  [Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes].

Authors:  Antonia Sambola; Valentín Fuster; Juan José Badimon
Journal:  Rev Esp Cardiol       Date:  2003-10       Impact factor: 4.753

7.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.

Authors:  R M Conroy; K Pyörälä; A P Fitzgerald; S Sans; A Menotti; G De Backer; D De Bacquer; P Ducimetière; P Jousilahti; U Keil; I Njølstad; R G Oganov; T Thomsen; H Tunstall-Pedoe; A Tverdal; H Wedel; P Whincup; L Wilhelmsen; I M Graham
Journal:  Eur Heart J       Date:  2003-06       Impact factor: 29.983

8.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

Review 9.  Varenicline: a novel pharmacotherapy for smoking cessation.

Authors:  Carlos Jiménez-Ruiz; Ivan Berlin; Thomas Hering
Journal:  Drugs       Date:  2009-07-09       Impact factor: 9.546

Review 10.  Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation.

Authors:  Gillian M Keating; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.